How many units of CJC-1295 DAC are in a dose?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds CJC-1295 with DAC and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    No label sets a dose for CJC-1295 with DAC; a review lists the regimen from peer-reviewed studies as 30 or 60 µg/kg SC, 2–3 times weekly or biweekly.1

    The guide's example

    1,000 mcg of CJC-1295 (with DAC) from a 2 mg vial mixed with 1 mL is 50 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water
    2 mg2 mg/mL: 500 mcg is 25 units, 1,000 mcg is 50 units1 mg/mL: 500 mcg is 50 units, 1,000 mcg is 100 units

    Vial strength and syringe units

    1,000 mcg of CJC-1295 (with DAC) from a 2 mg vial mixed with 1 mL is 50 units on a U-100 syringe.

    The calculator is at the top of the page

    One pharmacy listing shows CJC-1295 DAC sold as a 2 mg vial.2 No label or maker leaflet gives a water volume, so nothing fixes the syringe units for a 2 mg vial: the table is arithmetic for two assumed volumes and two example doses, 500 and 1000 mcg, that no label or leaflet sets.

    What the trials report

    No Milligram logged share for CJC-1295 with DAC is available.

    The human studies dose by body weight, in µg/kg; the Teichman 2006 report's summary gives neither the dose in each arm nor the number of people.3 Teichman and colleagues (2006), studying healthy adults aged 21-61, concluded that subcutaneous CJC-1295 was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg, and saw evidence of a cumulative effect after multiple doses.3

    TrialDose and schedulePeopleLength
    Teichman and colleagues, 2006 (two trials)3Under the skin: four ascending single doses in the first trial; two or three weekly or biweekly doses in the second; amounts per dose not in the summaryHealthy adults aged 21-61; number not in the summary28 and 49 d
    Ionescu and Frohman, 20064One injection of 60 or 90 microg/kgHealthy men aged 20 to 40; number not in the summarySampled before and 1 week after

    Registry, sponsor and forum figures

    The review that sums up the trials describes the human evidence for CJC-1295 with DAC as phase I PK/PD studies in healthy adults, with no controlled efficacy data.1 It gives the route as subcutaneous and the half-life as about 5.8–8 days in healthy adults.1 As a pattern from bodybuilding-related forums, which the review says is not evidence-based and must not be read as clinically validated or safe, it lists 1–2 mg per week SC in 1–2 injections, in cycles of 8–12 or 12–16 weeks on and 4–6 weeks off.1

    ClinicalTrials.gov lists a ConjuChem phase 2 trial, NCT00267527, in HIV patients with visceral obesity, randomised to low dose CJC 1295, high dose CJC 1295 or placebo for 12 weeks with a 6 week follow-up, and gives no dose amounts.5 It enrolled 120 people and ended with status terminated.5 ConjuChem's August 2006 release says its phase II trial of DAC(TM):GRF in HIV lipodystrophy had completed enrollment with 192 patients, and that patients were to be administered once-weekly dosing of DAC(TM):GRF for 12 weeks followed by a 6-week follow-up.6

    Frequently asked questions

    What do regulators say about CJC-1295 with DAC?

    The TGA, Australia's regulator, lists CJC-1295 among examples of unapproved peptide products, often supplied in injectable form, that it has not evaluated for safety, quality or effectiveness, and says important information such as how they are manufactured, whether they are sterile and what they contain remains unknown.7 The FDA says compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration, that it has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited.8

    How should CJC-1295 with DAC be stored?

    Neither a label nor a regulator gives a storage condition for the powder or a mixed vial.

    Did the trials report safety problems?

    Teichman and colleagues (2006) reported no serious adverse reactions in their two trials in healthy adults aged 21-61.3 ConjuChem's 2006 release reports that a patient in its phase II trial in HIV lipodystrophy had an acute myocardial infarction approximately two hours after the 11th weekly dose, with death approximately one hour later; the attending physician's most likely explanation was asymptomatic coronary artery disease, and the company terminated the study.6

    References

    1. Front Endocrinol. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
    2. FormBlends. CJC-1295 DAC: Benefits, Mechanism & Research Guide | FormBlends. formblends.com
    3. J Clin Endocrinol Metab. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. 2006. pubmed.ncbi.nlm.nih.gov
    4. J Clin Endocrinol Metab. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. 2006. pubmed.ncbi.nlm.nih.gov
    5. ClinicalTrials.gov. NCT00267527: A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. 2006. clinicaltrials.gov
    6. ConjuChem. Patient Died in Lipodystrophy Drug Study. web.archive.org
    7. TGA. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. tga.gov.au
    8. FDA. Substances in Compounding that May Present Significant Safety Risks. fda.gov